(Thyroid) Hormonal regulation of breast cancer cells

Thyroid hormone as L-thyroxine (T4) acts nongenomically at physiological concentrations at its cancer cell surface receptor on integrin αvβ3 ('thyrointegrin') to cause cancer cell proliferation. In the case of estrogen receptor (ERα)-positive breast cancer cells, T4 the integrin promotes E...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2023-01, Vol.13, p.1109555-1109555
Main Authors: Hercbergs, Aleck, Lin, Hung-Yun, Mousa, Shaker A, Davis, Paul J
Format: Article
Language:English
Subjects:
3’-triiodo-L-thyronine(T3)
breast cancer
Breast Neoplasms - drug therapy
Endocrinology
Estrogen Receptor alpha - metabolism
Female
Humans
integrin αvβ3
L-thyroxine (T4)
Thyroid Gland - metabolism
Thyroid Hormones - metabolism
Thyroxine - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thyroid hormone as L-thyroxine (T4) acts nongenomically at physiological concentrations at its cancer cell surface receptor on integrin αvβ3 ('thyrointegrin') to cause cancer cell proliferation. In the case of estrogen receptor (ERα)-positive breast cancer cells, T4 the integrin promotes ERα-dependent cancer growth in the absence of estrogen. Thus, tumor growth in the post-menopausal patient with ERα-positive cancer may again be ER-dependent because of T4. Additional mechanisms by which T4 may contribute uniquely to aggressive breast cancer behavior-independently of ER-are stimulation of immune checkpoint inhibitor gene expression and of several anti-apoptosis mechanisms. These observations may call for consideration of elimination of host T4 production in breast cancer patients whose response is suboptimal to standard chemotherapy regimens. Euthyroidism in such a setting may be maintained with exogenous 3,3',5-triiodo-L-thyronine (T3).
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.1109555